Vor Biopharma Inc. (VOR)
NASDAQ: VOR · Real-Time Price · USD
29.06
-1.16 (-3.84%)
At close: Oct 16, 2025, 4:00 PM EDT
29.13
+0.07 (0.24%)
Pre-market: Oct 17, 2025, 8:01 AM EDT

Vor Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022FY 2021FY 20202018 - 2019
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Selling, General & Admin
21.6527.8831.7228.8721.4911.75
Upgrade
Research & Development
315.0293.3194.3264.5547.5331.62
Upgrade
Operating Expenses
336.67121.19126.0493.4269.0243.37
Upgrade
Operating Income
-336.67-121.19-126.04-93.42-69.02-43.37
Upgrade
Interest & Investment Income
2.94.278.171.320.120.03
Upgrade
Other Non Operating Income (Expenses)
-1,300-----
Upgrade
Pretax Income
-1,664-116.91-117.86-92.09-68.9-43.34
Upgrade
Net Income
-1,664-116.91-117.86-92.09-68.9-43.34
Upgrade
Preferred Dividends & Other Adjustments
----1.235.93
Upgrade
Net Income to Common
-1,664-116.91-117.86-92.09-70.13-49.26
Upgrade
Shares Outstanding (Basic)
533220
Upgrade
Shares Outstanding (Diluted)
533220
Upgrade
Shares Change (YoY)
42.97%2.25%69.88%18.30%15547.86%-
Upgrade
EPS (Basic)
-342.66-34.03-35.08-46.57-41.95-4611.25
Upgrade
EPS (Diluted)
-342.66-34.03-35.08-46.57-41.95-4611.25
Upgrade
Free Cash Flow
-114.09-99.89-101.36-93.61-73.04-40.45
Upgrade
Free Cash Flow Per Share
-23.49-29.08-30.17-47.33-43.69-3786.67
Upgrade
EBITDA
-332.09-117.66-122.54-90.89-67.58-42.76
Upgrade
D&A For EBITDA
4.583.533.492.531.430.61
Upgrade
EBIT
-336.67-121.19-126.04-93.42-69.02-43.37
Upgrade
Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q